Clavis Pharma to present at the Rodman & Renshaw Annual Healthcare
Conference
(Thomson Reuters ONE) - Oslo, Norway, 8 September 2009Clavis Pharma ASA (OSE: CLAVIS) has been invited to present at theRodman & Renshaw Annual Healthcare Conference, New York, on Wednesday9 September 2009. Geir Christian Melen, CEO, will present the companyfrom 10:00 AM at The New York Palace Hotel, New York.The presentation will be webcast live and archived for 90 days on theClavis Pharma website at www.clavispharma.com.Geir Christian Melen will be available for one-on-one meetings duringthe Conference on 9-11 September 2009.For further information or booking of one-on-one meetings, pleasecontact:Geir Christian Melen, CEOOffice : +47 24 11 09 65Mobile : +47 91 30 29 65E-mail : geir.christian.melen(at)clavispharma.comGunnar Manum, CFOOffice : +47 24 11 09 71Mobile : +47 95 17 91 90E-mail : gunnar.manum(at)clavispharma.comAbout Clavis PharmaClavis Pharma ASA is an oncology focused pharmaceutical company usingits proprietary Lipid Vector Technology (LVT) platform to create NewChemical Entities (NCEs), by significantly improving alreadyestablished drugs. The improvements are achieved by chemicallybinding specific unsaturated lipids to existing, and well understood,approved pharmaceuticals. Data generated suggests the resultingpatentable NCEs offer improved efficacy and reduced side effectsthrough enhanced pharmacokinetic properties, greater tissuepenetration and, in many cases, additional modes of action.Clavis Pharma's objective is to develop its drug candidates untilsignificant value has been created and proof of principle in man hasbeen shown. For further clinical development and commercialisation ofthe products, Clavis Pharma will enter into strategic partnershipswith established pharmaceutical or biotech companies. The company'sproduct portfolio includes four new cancer drugs: Elacytarabine is inClinical Phase II, Intravenous CP-4126 is in Clinical Phase II, OralCP-4126 in Phase I, and CP-4200 is in preclinical development.Results indicate that these products have promising potential forseveral cancer indications within solid tumours and leukaemia.The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange(ticker: CLAVIS). Additional information on Clavis Pharma can befound at: http://www.clavispharma.com/.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 08.09.2009 - 10:00 Uhr
Sprache: Deutsch
News-ID 5588
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma to present at the Rodman & Renshaw Annual Healthcare
Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
